 Serine Endopeptidases
"Serine Endopeptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
| Descriptor ID |
D012697
|
| MeSH Number(s) |
D08.811.277.656.300.760 D08.811.277.656.959.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Serine Endopeptidases".
Below are MeSH descriptors whose meaning is more specific than "Serine Endopeptidases".
This graph shows the total number of publications written about "Serine Endopeptidases" by people in this website by year, and whether "Serine Endopeptidases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1981 | 0 | 1 | 1 | | 1986 | 1 | 0 | 1 | | 1989 | 0 | 3 | 3 | | 1990 | 1 | 2 | 3 | | 1991 | 1 | 1 | 2 | | 1992 | 4 | 4 | 8 | | 1993 | 7 | 1 | 8 | | 1994 | 2 | 1 | 3 | | 1995 | 1 | 4 | 5 | | 1996 | 7 | 5 | 12 | | 1997 | 2 | 0 | 2 | | 1998 | 11 | 1 | 12 | | 1999 | 5 | 2 | 7 | | 2000 | 5 | 0 | 5 | | 2001 | 4 | 3 | 7 | | 2002 | 4 | 1 | 5 | | 2003 | 3 | 4 | 7 | | 2004 | 6 | 1 | 7 | | 2005 | 2 | 2 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 2 | 1 | 3 | | 2010 | 3 | 1 | 4 | | 2011 | 5 | 1 | 6 | | 2012 | 1 | 6 | 7 | | 2013 | 5 | 1 | 6 | | 2014 | 3 | 5 | 8 | | 2015 | 2 | 5 | 7 | | 2016 | 1 | 2 | 3 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Serine Endopeptidases" by people in Profiles.
-
Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, Wu M, Spel L, Santoro S, Amoozgar Z, Laszewski T, Migoni SC, Knoblich K, Fletcher AL, LaFleur M, Wucherpfennig KW, Pure E, Dranoff G, Carroll MC, Turley SJ. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol Res. 2018 12; 6(12):1472-1485.
-
Belogortseva N, Krezalek M, Guyton K, Labno C, Poroyko V, Zaborina O, Alverdy JC. Media from macrophages co-incubated with Enterococcus faecalis induces epithelial cell monolayer reassembly and altered cell morphology. PLoS One. 2017; 12(8):e0182825.
-
Wang S, Kollipara RK, Humphries CG, Ma SH, Hutchinson R, Li R, Siddiqui J, Tomlins SA, Raj GV, Kittler R. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. Oncotarget. 2016 Oct 04; 7(40):64921-64931.
-
Stein EA. PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al. Cardiovasc Drugs Ther. 2016 10; 30(5):427-431.
-
Chan YK, Gack MU. A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. Nat Immunol. 2016 May; 17(5):523-30.
-
Ward JF, Eggener SE. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.
-
Stein EA, Raal FJ. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
-
Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015 Oct 27; 132(17):1648-66.
-
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL, Fitzgerald J, Checchia PA, Meyer K, Shanley TP, Quasney M, Hall M, Gedeit R, Freishtat RJ, Nowak J, Raj SS, Gertz S, Dawson E, Howard K, Harmon K, Lahni P, Frank E, Hart KW, Lindsell CJ. A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury. Crit Care Med. 2015 Aug; 43(8):1646-53.
-
Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 2015 Jul 24; 290(30):18609-20.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|